Pharmaceutical News

RSS

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd., for the joint discovery and development of new Affilin therapeutics to treat various diseases.

15 May 2012

Viewpoints: Approving drugs quickly; Berwick: In health care, cheaper can mean better; Health costs 'persistent' concern

For about 20 years, the Food and Drug Administration (FDA) has charged pharmaceutical companies "user fees" for reviewing drug-approval applications. The revenue allows the FDA to hire more evaluators, which allows useful drugs to reach patients faster. Now the Prescription Drug User Fee Act needs reauthorization, as it does every five years. Legislators should not dillydally.

15 May 2012

Five new capabilities added to Aetna Rx Check Program

Aetna today announced that it is adding five new capabilities to Aetna Rx Check, a collection of programs designed to promote safety and prevent the misuse of various prescription drugs such as pain medications and antibiotics.

15 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Menarini, Furiex enter license agreement to commercialize Priligy

Furiex Pharmaceuticals, Inc. and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East.

15 May 2012

Biovest plans to file BiovaxID MAA with EMA for treatment of follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest plans to file for marketing approval in the European Union (EU) for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

14 May 2012

S1 Biopharma announces foray into male sexual health with S1P-205

S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

14 May 2012

Medication nonadherence linked to unnecessary cardiovascular hospitalizations in older patients

Older patients with high cholesterol or high blood pressure are at particular risk for unnecessary hospitalizations if they don't follow doctor's orders on taking their medications, according to new research from Express Scripts presented this week.

14 May 2012

Event addresses FDA's recent draft guidelines for development of biosimilar products

Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.

14 May 2012

Beta blockers do not reduce risk of colorectal cancer

A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.

14 May 2012

Researchers uncover new way to stimulate activity of immune cell opiate receptors

Researchers at Rutgers University have uncovered a new way to stimulate activity of immune cell opiate receptors, leading to efficient tumor cell clearance.

14 May 2012

FDA ADAC recommends approval of Quad for HIV-1 infection

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.

14 May 2012

NBHA commends FDA for continuing investigation of bisphosphonate treatment for osteoporosis

In response to today's Perspective pieces published in the New England Journal Of Medicine, the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA) for continuing to investigate the risks and benefits of long-term bisphosphonate treatment.

11 May 2012

Anti-epilepsy drug phenobarbital stunts neuronal growth

A brain study in infant rats demonstrates that the anti-epilepsy drug phenobarbital stunts neuronal growth, which could prompt new questions about using the first-line drug to treat epilepsy in human newborns.

11 May 2012

FDA panel recommends approval of Truvada as preventive treatment for HIV

"In a move that could lead to a new milestone for treatment in the evolution of the worldwide AIDS epidemic," a Food and Drug Administration (FDA) panel on Thursday recommended Gilead Sciences' Truvada as a treatment for preventing HIV infection among healthy people at risk of contracting the virus, Reuters reports, noting, "It already has FDA approval to treat people infected with the human immunodeficiency virus".

11 May 2012

FDA advisory committee supports lorcaserin for weight management

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals.

11 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

Mylan Inc. today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the Netherlands and Ireland.

11 May 2012

CTI receives EU conditional marketing authorization for Pixuvri to treat non-Hodgkin B-cell lymphomas

CellTherapeutics today announced that it has received conditional marketing authorization from the European Commission for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixuvri is the first approved treatment in the European Union in this patient setting.

11 May 2012

HIV prevention drug receives FDA panel's backing

The drug has already been approved as a treatment for HIV/AIDS. The FDA is expected to decide about approval by June 15.

11 May 2012

Pharmaceutical News

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Viewpoints: Approving drugs quickly; Berwick: In health care, cheaper can mean better; Health costs 'persistent' concern

Five new capabilities added to Aetna Rx Check Program

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Menarini, Furiex enter license agreement to commercialize Priligy

Biovest plans to file BiovaxID MAA with EMA for treatment of follicular NHL

S1 Biopharma announces foray into male sexual health with S1P-205

Medication nonadherence linked to unnecessary cardiovascular hospitalizations in older patients

Event addresses FDA's recent draft guidelines for development of biosimilar products

Beta blockers do not reduce risk of colorectal cancer

Researchers uncover new way to stimulate activity of immune cell opiate receptors

FDA ADAC recommends approval of Quad for HIV-1 infection

NBHA commends FDA for continuing investigation of bisphosphonate treatment for osteoporosis

Anti-epilepsy drug phenobarbital stunts neuronal growth

FDA panel recommends approval of Truvada as preventive treatment for HIV

FDA advisory committee supports lorcaserin for weight management

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

CTI receives EU conditional marketing authorization for Pixuvri to treat non-Hodgkin B-cell lymphomas

HIV prevention drug receives FDA panel's backing

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News